Drug Approval | July 24, 2025
NATCO Pharma API unit in Mekaguda receives EIR from USFDA
The company received one observation in the Form-483
The company received one observation in the Form-483
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
She was Group Chief Marketing Officer at CKA Birla Group in her last role
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
Subscribe To Our Newsletter & Stay Updated
